Literature DB >> 6140941

Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation.

H R Ochs, D J Greenblatt, M Knüchel.   

Abstract

Healthy volunteers received a single dose of triazolam (0.5 mg) or oxazepam (30 mg) on two occasions, once in the control state and again during coadministration of isoniazid (INH) base, 180 mg day. INH coadministration prolonged triazolam half-life (3.3 vs 2.5 h, P less than 0.05) and increased total area under the curve (38.6 vs 26.5 ng ml-1 h, P less than 0.01) consistent with a reduction of apparent oral clearance (3.9 vs 6.8 ml min-1 kg-1, 0.05 less than P less than 0.1). INH coadministration had no influence on the kinetics of oxazepam. INH impairs hepatic microsomal oxidation of triazolam, leading to reduced first-pass hepatic extraction as well as prolonged half-life. However INH had no influence on oxazepam conjugation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140941      PMCID: PMC1428351          DOI: 10.1111/j.1365-2125.1983.tb02256.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

Authors:  D J Greenblatt; K Franke; R I Shader
Journal:  J Chromatogr       Date:  1978-09-01

3.  Diphenylhydantoin intoxication. A complication of isoniazid therapy.

Authors:  H Kutt; R Brennan; H Dehejia; K Verebely
Journal:  Am Rev Respir Dis       Date:  1970-03

4.  Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program.

Authors:  R R Miller; J Porter; D J Greenblatt
Journal:  Chest       Date:  1979-03       Impact factor: 9.410

5.  Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism.

Authors:  S F Muakkassah; W R Bidlack; W C Yang
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

Review 6.  Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

9.  Diazepam interaction with antituberculosis drugs.

Authors:  H R Ochs; D J Greenblatt; G M Roberts; H J Dengler
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

10.  Triazolam disposition.

Authors:  F S Eberts; Y Philopoulos; L M Reineke; R W Vliek
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

View more
  14 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Authors:  Lei Cao; David J Greenblatt; Awewura Kwara
Journal:  Drug Metab Dispos       Date:  2017-06-29       Impact factor: 3.922

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 6.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

7.  An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.

Authors:  Thomas M Polasek; David J Elliot; Andrew A Somogyi; Elizabeth M J Gillam; Benjamin C Lewis; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

Review 8.  Pharmacokinetics of the newer benzodiazepines.

Authors:  P D Garzone; P D Kroboth
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

9.  Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol.

Authors:  H R Ochs; D J Greenblatt; B Verburg-Ochs; J S Harmatz; H Grehl
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Lack of influence of cigarette smoking on triazolam pharmacokinetics.

Authors:  H R Ochs; D J Greenblatt; E S Burstein
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.